To get the pdf of the paper, click here
Source: Nature AOP doi:10.1038/nature07999
Abstract:
Common genetic variants on 5p14.1 associate with autism spectrum disorders
Kai Wang et al.
Autism spectrum disorders (ASDs) represent a group of childhood neurodevelopmental and neuropsychiatric disorders characterized by deficits in verbal communication, impairment of social interaction, and restricted and repetitive patterns of interests and behaviour. To identify common genetic risk factors underlying ASDs, here we present the results of genome-wide association studies on a cohort of 780 families (3,101 subjects) with affected children, and a second cohort of 1,204 affected subjects and 6,491 control subjects, all of whom were of European ancestry. Six single nucleotide polymorphisms between cadherin 10 (CDH10) and cadherin 9 (CDH9)—two genes encoding neuronal cell-adhesion molecules—revealed strong association signals, with the most significant SNP being rs4307059 (P53.431028, odd ratio51.19). These signals were replicated in two independent cohorts, with combined P values ranging from 7.431028 to 2.1310210. Our results implicate neuronal cell-adhesion molecules in the pathogenesis of ASDs, and represent, to our knowledge, the first demonstration of genome-wide significant association of common variants with susceptibility to ASDs.
Subscribe to:
Post Comments (Atom)
Posts
For the last two years, our affiliate physicians abraod, have treated 20 autistic children under the age of 12 (prior to blood brain barrier formation) with precursor fetal stem cell xeno transplantation (“SCXT”). The children where “gluteally” injected with fetal cells tissues of (periventricular) medulla Alba of brain, rhienecephon, hippocampus, temporal lobe of brain, frontal lobe of brain, brain cortex, and thalamus. Prospective data is currently being gathered to evidence the degrees of success from “significant” to “miraculous” Licensed physicians under the supervision of Dr. Molnar, performed the implantations.
ReplyDeleteTwo months ago, Dr. Molnar’s team treated a three-month-old baby from Southern California diagnosed with Down syndrome via chromosome analysis (abnormal karotype). Last week the parents sent the following up date
Hi Greg,
Merryn had her 6 months check up done this week. Everything looks fine. Her pediatrician can see a change in her facial appearance. Her eye shapes are slowly changing. Her body weight, height and head
circumference is 90% and 75% respectively based on normal children's growth chart.
Given this progress, we definitely want to continue with the treatment. As I recall from the conversation with Dr. Molnar, Merryn's next treatment should be done 4 months after the 1st one, which would put her somewhere at the end of June or early July
The purpose of my email is to see if your readers have interest in learning more about the success our doctors are having treating both autism and Down syndrome SUCCESSFULLY! By the way, Dr. Molnar treated over 350 Down syndrome patients in the former Soviet Union from 1989 to 1997 with SCXT.
Regards,
Gregory C. DiRienzo
001-949-939-0050
For the last two years, our affiliate physicians abroad have treated 20 autistic children under the age of 12 (prior to blood brain barrier formation) with precursor fetal stem cell xeno transplantation (“SCXT”). The children where “gluteally” injected with fetal cells tissues of (periventricular) medulla Alba of brain, rhienecephon, hippocampus, temporal lobe of brain, frontal lobe of brain, brain cortex, and thalamus. Prospective data is currently being gathered to evidence the degrees of success from “significant” to “miraculous” Licensed physicians under the supervision of E Michael Molnar MD, a world authority on SCXT, performed the implantations.
ReplyDeleteTwo months ago, Dr. Molnar’s team treated a three-month-old baby from Southern California diagnosed with Down syndrome, via chromosome analysis (abnormal karotype). Last week the parents sent the following up date
Hi Greg,
Merryn had her 6 months check up done this week. Everything looks fine. Her pediatrician can see a change in her facial appearance. Her eye shapes are slowly changing. Her body weight, height, and head circumference is 90% and 75% respectively based on normal children's growth chart.
Given this progress, we definitely want to continue with the treatment. As I recall from the conversation with Dr. Molnar, Merryn's next treatment should be done 4 months after the 1st one, which would put her somewhere at the end of June or early July
The purpose of my email is to see if any of your readers have interest in learning more about the success these doctors are having successfully treating both autism and Down syndrome with SCXT! By the way, Dr. Molnar treated over 350 Down syndrome patients in the former Soviet Union from 1989 to 1997 with SCXT.
Regards,
Gregory C. DiRienzo
(001)-949-939-0050
(gcdsocal@cox.net)